Biovitrum Enters Development Agreement with Swedish Biotech Company Synphora
11-Oct-2006 -
Biovitrum has entered an agreement with the Uppsala-based biotech company Synphora regarding a new drug candidate (JB991) for the treatment of the skin disease psoriasis and other conditions. JB991 is a prostaglandin derivative, i. e. a substance which is based on prostaglandin, a local hormone ...
Biovitrum
Hormone
inflammation